Endocrine Abstracts

Objective: Rimonabant has been shown to reduce weight, free androgen index (FAI) and insulin resistance in obese patients with PCOS compared to metformin. Metformin has also been shown to maintain the weight loss and enhance the metabolic and biochemical parameters achieved by treatment with rimonabant. We have determined the effect of rimonabant on the incretin hormones in patients with PCOS.Design: A randomized open labelled parallel study of metformin...